S K Kelley

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi request reprint Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety
    S K Kelley
    Department of Pharmacologic Sciences, Genentech, Inc, South San Francisco, California, USA
    J Pharmacol Exp Ther 299:31-8. 2001

Detail Information

Publications1

  1. ncbi request reprint Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety
    S K Kelley
    Department of Pharmacologic Sciences, Genentech, Inc, South San Francisco, California, USA
    J Pharmacol Exp Ther 299:31-8. 2001
    ..In conclusion, these studies have characterized the disposition of Apo2L/TRAIL in rodents and primates and provide information that will be used to predict the pharmacokinetics of Apo2L/TRAIL in humans...